{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:38:03Z","timestamp":1793831883877,"version":"4.6.1"},"reference-count":44,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Unexpected low responders are patients with normal ovarian reserve tests who exhibit suboptimal responses to stimulation but have promising treatment potential due to adequate follicle availability. This study aimed to compare the live birth rates (LBRs) between fixed and flexible gonadotropin-releasing hormone antagonist (GnRH-ant) protocols in low-prognosis patients from Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number (POSEIDON) groups 1 and 2. Methods: This retrospective cohort study included 117 women classified as POSEIDON groups 1 and 2 who underwent GnRH-ant protocols for in vitro fertilization (IVF)\/Intracytoplasmic Sperm Injection (ICSI) at the Petrova Maternity Hospital in Zagreb (2019\u20132020). The primary outcome analyzed was the live birth rate (LBR). The secondary outcomes were the GnRH start day, duration of gonadotropin therapy, number of oocytes, number of embryos, number of blastocysts, number of third-day embryos, number of vitrified embryos, positive pregnancy test, clinical pregnancy, and miscarriage rate. Group comparisons were conducted using Mann\u2013Whitney and chi-squared tests. Results: In POSEIDON group 1, the fixed protocol significantly improved outcomes, with higher rates of clinical pregnancy, 12-week ongoing pregnancy, and LBRs (58.8% vs. 8.3%). More fresh transferable embryos were also noted (p &lt; 0.05). In POSEIDON group 2, no significant differences were observed between protocols for any outcomes. Conclusions: The fixed GnRH-ant protocol improved pregnancy outcomes for POSEIDON group 1 but showed no advantage over the flexible protocol in POSEIDON group 2.<\/jats:p>","DOI":"10.3390\/jcm14061901","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T04:55:44Z","timestamp":1741755344000},"page":"1901","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Does the Timing of Antagonist Treatment Influence Cycle Outcomes in Unexpected Low Responders of POSEIDON Class 1 and 2?"],"prefix":"10.3390","volume":"14","author":[{"given":"Nina","family":"Medi\u0107","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Clinical Hospital Sveti Duh, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1557-9628","authenticated-orcid":false,"given":"Damir","family":"Roje","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Split University Hospital Center, 21000 Split, Croatia"},{"name":"Department of Obstetrics and Gynecology, School of Medicine, University of Split, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1747-204X","authenticated-orcid":false,"given":"Marina \u0160prem","family":"Gold\u0161tajn","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Clinical Hospital Center, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Conforti, A., Esteves, S.C., Cimadomo, D., Vaiarelli, A., Di Rella, F., Ubaldi, F.M., Zullo, F., De Placido, G., and Alviggi, C. (2019). Management of Women With an Unexpected Low Ovarian Response to Gonadotropin. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00387"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/GCO.0000000000000452","article-title":"What is new in the management of poor ovarian response in IVF?","volume":"30","author":"Vaiarelli","year":"2018","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2633494120941480","DOI":"10.1177\/2633494120941480","article-title":"Update on the management of poor ovarian response in IVF: The shift from Bologna criteria to the Poseidon concept","volume":"14","author":"Drakopoulos","year":"2020","journal-title":"Ther. Adv. Reprod. Health"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/humrep\/der092","article-title":"ESHRE consensus on the definition of \u2018poor response\u2019 to ovarian stimulation for in vitro fertilization: The Bologna criteria","volume":"26","author":"Ferraretti","year":"2011","journal-title":"Hum. Reprod."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.fertnstert.2011.09.048","article-title":"A systematic review of randomized trials for the treatment of poor ovarian responders: Is there any light at the end of the tunnel?","volume":"96","author":"Polyzos","year":"2011","journal-title":"Fertil. Steril."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13048-015-0204-9","article-title":"The Bologna criteria for poor ovarian response: A contemporary critical appraisal","volume":"8","author":"Younis","year":"2015","journal-title":"J. Ovarian Res."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Abu-Musa, A., Haahr, T., and Humaidan, P. (2020). Novel Physiology and Definition of Poor Ovarian Response; Clinical Recommendations. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21062110"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.fertnstert.2016.02.005","article-title":"A new more detailed stratification of low responders to ovarian stimulation: From a poor ovarian response to a low prognosis concept","volume":"105","author":"Alviggi","year":"2016","journal-title":"Fertil. Steril."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Esteves, S.C., Roque, M., Bedoschi, G.M., Conforti, A., Humaidan, P., and Alviggi, C. (2018). Defining Low Prognosis Patients Undergoing Assisted Reproductive Technology: POSEIDON Criteria\u2014The Why. Front. Endocrinol., 9.","DOI":"10.3389\/fendo.2018.00461"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1093\/humrep\/deab152","article-title":"Cumulative delivery rate per aspiration IVF\/ICSI cycle in POSEIDON patients: A real-world evidence study of 9073 patients","volume":"36","author":"Esteves","year":"2021","journal-title":"Hum. Reprod."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Lee, H.J., Noh, H.K., and Joo, J.K. (2022). Comparison of ART outcome in patients with poor ovarian response according to POSEIDON criteria. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-22859-w"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bpobgyn.2022.05.003","article-title":"POSEIDON groups and their distinct reproductive outcomes: Effectiveness and cost-effectiveness insights from real-world data research","volume":"85","author":"Esteves","year":"2022","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/humrep\/deab068","article-title":"The effect of polymorphisms in FSHR and FSHB genes on ovarian response: A prospective multicenter multinational study in Europe and Asia","volume":"36","author":"Polyzos","year":"2021","journal-title":"Hum. Reprod."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1007\/s43032-024-01700-x","article-title":"The Additive Effect of Combinations of FSH Receptor Gene Variants in Ovarian Response to Stimulation","volume":"31","author":"Neves","year":"2024","journal-title":"Reprod. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Baldini, G.M., Catino, A., Palini, S., Sciorio, R., Ferri, D., Vinciguerra, M., and Baldini, D. (2023). The Polymorphism Asn680Ser on the FSH Receptor and Abnormal Ovarian Response in Patients with Normal Values of AMH and AFC. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021080"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Alviggi, C., Conforti, A., Esteves, S.C., Vallone, R., Venturella, R., Staiano, S., Castaldo, E., Andersen, C.Y., and De Placido, G. (2018). Understanding Ovarian Hypo-Response to Exogenous Gonadotropin in Ovarian Stimulation and Its New Proposed Marker\u2014The Follicle-To-Oocyte (FOI) Index. Front. Endocrinol., 9.","DOI":"10.3389\/fendo.2018.00589"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Conforti, A., T\u00fcttelmann, F., Alviggi, C., Behre, H.M., Fischer, R., Hu, L., Polyzos, N.P., Chuderland, D., Rama Raju, G.A., and D\u2019Hooghe, T. (2022). Effect of Genetic Variants of Gonadotropins and Their Receptors on Ovarian Stimulation Outcomes: A Delphi Consensus. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.797365"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1093\/humrep\/dev149","article-title":"Sub-optimal responders following controlled ovarian stimulation: An overlooked group?","volume":"30","author":"Polyzos","year":"2015","journal-title":"Hum. Reprod."},{"key":"ref_19","first-page":"124","article-title":"Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: From theory to practice","volume":"20","author":"Sunkara","year":"2013","journal-title":"Hum. Reprod. Update"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Sunkara, S.K., Ramaraju, G.A., and Kamath, M.S. (2020). Management Strategies for POSEIDON Group 2. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.00105"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Orvieto, R., Venetis, C.A., Fatemi, H.M., D\u2019Hooghe, T., Fischer, R., Koloda, Y., Horton, M., Grynberg, M., Longobardi, S., and Esteves, S.C. (2021). Optimising Follicular Development, Pituitary Suppression, Triggering and Luteal Phase Support During Assisted Reproductive Technology: A Delphi Consensus. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.675670"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/humupd\/dml001","article-title":"GnRH antagonists in ovarian stimulation for IVF","volume":"12","author":"Tarlatzis","year":"2006","journal-title":"Hum. Reprod. Update"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Copperman, A.B., and Benadiva, C. (2013). Optimal usage of the GnRH antagonists: A review of the literature. Reprod. Biol. Endocrinol., 11.","DOI":"10.1186\/1477-7827-11-20"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/humupd\/dml038","article-title":"Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis","volume":"12","author":"Kolibianakis","year":"2006","journal-title":"Hum. Reprod. Update"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e23933","DOI":"10.1016\/j.heliyon.2023.e23933","article-title":"Ovarian response determines the luteinizing hormone suppression threshold for patients following the gonadotrophin releasing hormone antagonist protocol: A retrospective cohort study","volume":"10","author":"Li","year":"2024","journal-title":"Heliyon"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/humupd\/dmx017","article-title":"GnRH antagonist versus long agonist protocols in IVF: A systematic review and meta-analysis accounting for patient type","volume":"23","author":"Lambalk","year":"2017","journal-title":"Hum. Reprod. Update"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/humupd\/dmac040","article-title":"What is the optimal GnRH antagonist protocol for ovarian stimulation during ART treatment? A systematic review and network meta-analysis","volume":"29","author":"Venetis","year":"2023","journal-title":"Hum. Reprod. Update"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Humaidan, P., La Marca, A., Alviggi, C., Esteves, S.C., and Haahr, T. (2019). Future Perspectives of POSEIDON Stratification for Clinical Practice and Research. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00439"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0015-0282(02)04920-8","article-title":"Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy","volume":"79","author":"Kolibianakis","year":"2003","journal-title":"Fertil. Steril."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.fertnstert.2013.05.031","article-title":"Early initiation of gonadotropin-releasing hormone antagonist treatment results in a more stable endocrine milieu during the mid- and late-follicular phases: A randomized controlled trial comparing gonadotropin-releasing hormone antagonist initiation on cycle day 2 or 6","volume":"100","author":"Hamdine","year":"2013","journal-title":"Fertil. Steril."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/humrep\/der106","article-title":"Association between the number of eggs and live birth in IVF treatment: An analysis of 400 135 treatment cycles","volume":"26","author":"Sunkara","year":"2011","journal-title":"Hum. Reprod."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"18331","DOI":"10.18632\/aging.203282","article-title":"Prediction of pregnancy outcome in fresh in vitro fertilization\/intracytoplasmic sperm injection treatment in patients with poor ovarian reserve","volume":"13","author":"Chen","year":"2021","journal-title":"Aging"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Esteves, S.C., Alviggi, C., Humaidan, P., Fischer, R., Andersen, C.Y., Conforti, A., B\u00fchler, K., Sunkara, S.K., Polyzos, N.P., and Galliano, D. (2019). The POSEIDON Criteria and Its Measure of Success Through the Eyes of Clinicians and Embryologists. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00814"},{"key":"ref_34","first-page":"CD002118","article-title":"Cleavage stage versus blastocyst stage embryo transfer in assisted reproductive technology","volume":"30","author":"Glujovsky","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.fertnstert.2005.05.040","article-title":"Serum luteinizing hormone in patients undergoing ovarian stimulation with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating hormone and its relationship with cycle outcome","volume":"84","author":"Bosch","year":"2005","journal-title":"Fertil. Steril."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/humrep\/deh334","article-title":"The effect of an individualized GnRH antagonist protocol on folliculogenesis in IVF\/ICSI","volume":"19","author":"Mochtar","year":"2004","journal-title":"Hum. Reprod."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1093\/humrep\/17.11.2842","article-title":"Tailoring the GnRH antagonist cetrorelix acetate to individual patients\u2019 needs in ovarian stimulation for IVF: Results of a prospective, randomized study","volume":"17","author":"Ludwig","year":"2002","journal-title":"Hum. Reprod."},{"key":"ref_38","first-page":"175","article-title":"Endogenous luteinizing hormone concentration and IVF outcome during ovarian stimulation in fixed versus flexible GnRH antagonist protocols: An RCT","volume":"16","author":"Depalo","year":"2018","journal-title":"Int. J. Reprod. Biomed."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.repbio.2020.04.004","article-title":"The association between treatment parameters on the day of gonadotropin-releasing hormone antagonist initiation during a flexible protocol and oocyte maturation rate","volume":"20","author":"Wertheimer","year":"2020","journal-title":"Reprod. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0950-3552(05)80073-2","article-title":"Immunocytochemical localization of oestradiol and progesterone receptors in human endometrium: A tool to assess endometrial maturation","volume":"5","author":"Bouchard","year":"1991","journal-title":"Bailliere\u2019s Clin. Obstet. Gynaecol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0015-0282(02)03323-X","article-title":"Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up","volume":"78","author":"Kolibianakis","year":"2002","journal-title":"Fertil. Steril."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Han, Q.-S., Zhou, Y., Xu, Y., Ai, K.-L., Song, J.-Y., and Sun, Z.-G. (2024). Optimal timing of GnRH antagonist initiation in IVF-ET: A retrospective cohort study on advanced maternal age women. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1340230"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/humrep\/deh601","article-title":"Dose-finding study of daily GnRH antagonist for the prevention of premature LH surges in IVF\/ICSI patients: Optimal changes in LH and progesterone for clinical pregnancy","volume":"20","author":"Huirne","year":"2005","journal-title":"Hum. Reprod."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S1472-6483(10)61661-6","article-title":"Optimizing GnRH antagonist administration: Meta-analysis of fixed versus flexible protocol","volume":"10","author":"Aboulghar","year":"2005","journal-title":"Reprod. BioMed. Online"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/6\/1901\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:50:59Z","timestamp":1760028659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/6\/1901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["jcm14061901"],"URL":"https:\/\/doi.org\/10.3390\/jcm14061901","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]}}}